{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:47:47Z","timestamp":1782535667073,"version":"3.54.5"},"reference-count":53,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2024YFC2311500"],"award-info":[{"award-number":["2024YFC2311500"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Human respiratory syncytial virus (HRSV) is a major cause of severe lower respiratory tract infections in infants, young children, and older adults worldwide. With the approval of nirsevimab and HRSV vaccines, accurate measurement of neutralizing antibody levels has become essential for vaccine evaluation, immunization strategy design, and seroepidemiology. The plaque reduction neutralization test (PRNT) remains the gold standard, but it is slow, low-throughput, and requires high biosafety. In recent years, newer methods including focus reduction neutralization testing (FRNT), pseudovirus neutralization testing (PNT), and fluorescent\/luminescent reporter virus systems (RVSs) have improved speed and throughput while maintaining high specificity. This review summarizes the principles, performance, applications, and standardization challenges of these assays, offering methodological guidance for HRSV research and prevention in China.<\/jats:p>","DOI":"10.3390\/vaccines14060550","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T03:09:17Z","timestamp":1782270557000},"page":"550","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in Detection Methods for Human Respiratory Syncytial Virus Neutralizing Antibodies"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6660-7518","authenticated-orcid":false,"given":"Qi","family":"Shen","sequence":"first","affiliation":[{"name":"Institute of Microbiology Laboratory, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 201107, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Gai","sequence":"additional","affiliation":[{"name":"Institute of Microbiology Laboratory, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 201107, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiu","family":"Zhou","sequence":"additional","affiliation":[{"name":"Institute of Microbiology Laboratory, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 201107, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Virant, M.J., Lu\u0161trek, M., Kogoj, R., Petrovec, M., and Ur\u0161i\u010d, T. (2023). Changes in HRSV Epidemiology but Not Circulating Variants in Hospitalized Children due to the Emergence of SARS-CoV-2. Viruses, 15.","DOI":"10.3390\/v15061218"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Gong, X., Luo, E., Fan, L., Zhang, W., Yang, Y., Du, Y., Yang, X., and Xing, S. (2024). Clinical research on RSV prevention in children and pregnant women: Progress and perspectives. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1329426"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"106567","DOI":"10.1016\/j.jinf.2025.106567","article-title":"Evolutionary dynamics of HRSV following the implementation of nirsevimab immunoprophylaxis in Catalonia (2023-2024)","volume":"91","author":"Coma","year":"2025","journal-title":"J. Infect."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"25151355241310601","DOI":"10.1177\/25151355241310601","article-title":"The recent landscape of RSV vaccine research","volume":"13","author":"Kelleher","year":"2025","journal-title":"Ther. Adv. Vaccines Immunother."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Agac, A., Kolbe, S.M., Ludlow, M., Osterhaus, A.D.M.E., Meineke, R., and Rimmelzwaan, G.F. (2023). Host Responses to Respiratory Syncytial Virus Infection. Viruses, 15.","DOI":"10.3390\/v15101999"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Ou, L., Chen, S.J., Teng, I.T., Yang, L., Zhang, B., Zhou, T., Biju, A., Cheng, C., Kong, W.P., and Morano, N.C. (2023). Structure-based design of a single-chain triple-disulfide-stabilized fusion-glycoprotein trimer that elicits high-titer neutralizing responses against human metapneumovirus. PLoS Pathog., 19.","DOI":"10.1371\/journal.ppat.1011584"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"eade6422","DOI":"10.1126\/scitranslmed.ade6422","article-title":"Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine","volume":"15","author":"Che","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e2024067174","DOI":"10.1542\/peds.2024-067174","article-title":"RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing","volume":"154","author":"Wilkins","year":"2024","journal-title":"Pediatrics"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/AOG.0000000000005816","article-title":"Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial","volume":"145","author":"Pahud","year":"2025","journal-title":"Obstet. Gynecol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e996","DOI":"10.1093\/infdis\/jiae316","article-title":"Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults","volume":"230","author":"Goswami","year":"2024","journal-title":"J. Infect. Dis."},{"key":"ref_11","first-page":"959","article-title":"Establishment and preliminary application of neutralizing antibody detection method for human respiratory syncytial virus","volume":"58","author":"Zhang","year":"2024","journal-title":"Zhonghua Yu Fang Yi Xue Za Zhi"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jviromet.2004.02.020","article-title":"A simplified plaque assay for respiratory syncytial virus--direct visualization of plaques without immunostaining","volume":"120","year":"2004","journal-title":"J. Virol. Methods"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/infdis\/jiad281","article-title":"Evaluation of the Live-Attenuated Intranasal Respiratory Syncytial Virus (RSV) Vaccine RSV\/6120\/\u0394NS2\/1030s in RSV-Seronegative Young Children","volume":"229","author":"Karron","year":"2024","journal-title":"J. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/infdis\/jiz408","article-title":"Safety and Immunogenicity of the Respiratory Syncytial Virus Vaccine RSV\/\u0394NS2\/\u03941313\/I1314L in RSV-Seronegative Children","volume":"222","author":"Karron","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"113054","DOI":"10.1016\/j.jim.2021.113054","article-title":"Development and qualification of a fast, high-throughput and robust imaging-based neutralization assay for respiratory syncytial virus","volume":"494","author":"Sun","year":"2021","journal-title":"J. Immunol. Methods"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biologicals.2021.10.001","article-title":"Development and comparison of three cell-based potency assays for anti-respiratory syncytial virus monoclonal antibody","volume":"74","author":"Sun","year":"2021","journal-title":"Biologicals"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Vaidya, S.R. (2023). Immuno-Colorimetric Neutralization Test: A Surrogate for Widely Used Plaque Reduction Neutralization Tests in Public Health Virology. Viruses, 15.","DOI":"10.3390\/v15040939"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e0086024","DOI":"10.1128\/msphere.00860-24","article-title":"Functional implications of respiratory syncytial virus F sequence variability: A comparative analysis using contemporary RSV isolates","volume":"10","author":"Stobbelaar","year":"2025","journal-title":"mSphere"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jim.2017.03.020","article-title":"A rapid, simple, and accurate plaque assay for human respiratory syncytial virus (HRSV)","volume":"446","author":"Kim","year":"2017","journal-title":"J. Immunol. Methods"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1743-422X-2-84","article-title":"Development of an improved microneutralization assay for respiratory syncytial virus by automated plaque counting using imaging analysis","volume":"2","author":"Zielinska","year":"2005","journal-title":"Virol. J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1016\/j.vaccine.2021.06.016","article-title":"RSV neutralization assays-Use in immune response assessment","volume":"39","author":"Raghunandan","year":"2021","journal-title":"Vaccine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e0173925","DOI":"10.1128\/spectrum.01739-25","article-title":"Corrected and republished from: \u201cClinical validation of an RSV neutralization assay and analysis of cross-sectional sera associated with 2021-2023 RSV outbreaks to investigate the immunity debt hypothesis\u201d","volume":"14","author":"Piliper","year":"2026","journal-title":"Microbiol. Spectr."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Vial, C., Whitaker, A., Wilhelm, J., Ovalle, J., Perez, R., Valdivieso, F., Ferres, M., Martinez-Valdebenito, C., Eisenhauer, P., and Mertz, G.J. (2020). Comparison of VSV Pseudovirus and Focus Reduction Neutralization Assays for Measurement of Anti-Andes orthohantavirus Neutralizing Antibodies in Patient Samples. Front. Cell Infect. Microbiol., 10.","DOI":"10.3389\/fcimb.2020.00444"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Hu, L., Jiang, J., Tang, Y., Mei, L., Wu, L., Li, L., Chen, H., Long, F., Xiao, J., and Peng, T. (2023). A Pseudovirus-Based Entry Assay to Evaluate Neutralizing Activity against Respiratory Syncytial Virus. Viruses, 15.","DOI":"10.3390\/v15071548"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jviromet.2018.01.003","article-title":"High degree of correlation between Ebola virus BSL-4 neutralization assays and pseudotyped VSV BSL-2 fluorescence reduction neutralization test","volume":"254","author":"Konduru","year":"2018","journal-title":"J. Virol. Methods"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Ramos-Cela, M., Forconi, V., Antonelli, R., Manenti, A., and Montomoli, E. (2025). Exploring the Use of Viral Vectors Pseudotyped with Viral Glycoproteins as Tools to Study Antibody-Mediated Neutralizing Activity. Microorganisms, 13.","DOI":"10.3390\/microorganisms13081785"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Zhao, Y., Wang, C., Zhou, Y., Yuan, H., Li, X., Wang, Y., and Pan, X. (2026). Application of Orthoflavivirus Pseudovirus Technology in Antiviral Research. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27020722"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e0103222","DOI":"10.1128\/aac.01032-22","article-title":"Respiratory Syncytial Virus Two-Step Infection Screen Reveals Inhibitors of Early and Late Life Cycle Stages","volume":"66","author":"Sake","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/s41467-024-45241-y","article-title":"Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor","volume":"15","author":"Sake","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/B978-0-12-380860-8.00004-5","article-title":"Cell entry of enveloped viruses","volume":"73","author":"Cosset","year":"2011","journal-title":"Adv. Genet."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41392-024-01858-5","article-title":"Farnesyltransferase inhibitor lonafarnib suppresses respiratory syncytial virus infection by blocking conformational change of fusion glycoprotein","volume":"9","author":"Yang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Denani, C.B., Setatino, B.P., Pereira, D., Horbach, I.S., Azevedo, A.S., Coutinho, G., Ferroco, C.L., Xavier, J., Leite, R., and Santos, E. (2025). Pseudovirus-Based Neutralization Assays as Customizable and Scalable Tools for Serological Surveillance and Immune Profiling. Pathogens, 14, Erratum in Pathogens 2026, 15, 173. https:\/\/doi.org\/10.3390\/pathogens15020173.","DOI":"10.3390\/pathogens15020173"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Isaacs, A., Cheung, S.T.M., Thakur, N., Jaberolansar, N., Young, A., Modhiran, N., Bailey, D., Graham, S.P., Young, P.R., and Chappell, K.J. (2021). Combinatorial F-G Immunogens as Nipah and Respiratory Syncytial Virus Vaccine Candidates. Viruses, 13.","DOI":"10.3390\/v13101942"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Huang, K., Ying, T., and Wu, Y. (2022). Single-Domain Antibodies as Therapeutics for Respiratory RNA Virus Infections. Viruses, 14.","DOI":"10.3390\/v14061162"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e0053125","DOI":"10.1128\/jvi.00531-25","article-title":"RSV F evolution escapes some monoclonal antibodies but does not strongly erode neutralization by human polyclonal sera","volume":"99","author":"Simonich","year":"2025","journal-title":"J. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Simonich, C.A.L., McMahon, T.E., Kampman, L., Chu, H.Y., and Bloom, J.D. (2026). Complete definition of how mutations affect antibodies used to prevent RSV. bioRxiv.","DOI":"10.64898\/2026.02.12.705519"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Praditya, D.F., Waluyo, D., and Nozaki, T. (2025). Reporter-expressing viruses for antiviral drug discovery research. Front. Cell Infect. Microbiol., 15.","DOI":"10.3389\/fcimb.2025.1645104"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1128\/JVI.03587-14","article-title":"Recombinant subgroup B human respiratory syncytial virus expressing enhanced green fluorescent protein efficiently replicates in primary human cells and is virulent in cotton rats","volume":"89","author":"Lemon","year":"2015","journal-title":"J. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jim.2010.08.005","article-title":"A flow cytometry-based assay to assess RSV-specific neutralizing antibody is reproducible, efficient and accurate","volume":"362","author":"Chen","year":"2010","journal-title":"J. Immunol. Methods"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.1038\/ncomms6104","article-title":"Visualizing the replication of respiratory syncytial virus in cells and in living mice","volume":"5","author":"Sourimant","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13567-023-01165-x","article-title":"Screening antivirals with a mCherry-expressing recombinant bovine respiratory syncytial virus: A proof of concept using cyclopamine","volume":"54","author":"Fix","year":"2023","journal-title":"Vet. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1093\/infdis\/jiac295","article-title":"Retinoic Acid-Inducible Gene I Activation Inhibits Human Respiratory Syncytial Virus Replication in Mammalian Cells and in Mouse and Ferret Models of Infection","volume":"226","author":"Schwab","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e0012725","DOI":"10.1128\/msphere.00127-25","article-title":"Can plitidepsin be used as an antiviral against RSV?","volume":"10","author":"Estampes","year":"2025","journal-title":"mSphere"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Yamagata, Y., Toizumi, M., Eleouet, J.-F., Rameix-Welti, M.-A., Takeda, M., and Yoshida, L.-M. (2025). Improved RSV Neutralization Assay Using Recombinant RSV Expressing Reporter Fluorescent Protein. Methods Protoc., 8.","DOI":"10.3390\/mps8030060"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1473-3099(24)00589-9","article-title":"Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: An observer-blinded, placebo-controlled, randomised, phase 3 trial","volume":"25","author":"Goswami","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1038\/s41467-025-56302-1","article-title":"A truncated pre-F protein mRNA vaccine elicits an enhanced immune response and protection against respiratory syncytial virus","volume":"16","author":"Lin","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e70173","DOI":"10.1111\/irv.70173","article-title":"Genomic Insights Into Respiratory Syncytial Virus Circulation Patterns and Neutralization by Anti-F Monoclonal Antibodies in Panama (2018\u20142024)","volume":"19","author":"Franco","year":"2025","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.immuni.2017.01.010","article-title":"Respiratory Syncytial Virus Infects Regulatory B Cells in Human Neonates via Chemokine Receptor CX3CR1 and Promotes Lung Disease Severity","volume":"46","author":"Zhivaki","year":"2017","journal-title":"Immunity"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Svensson, L., Nordgren, J., Lundkvist, \u00c5., and Hagbom, M. (2025). Recent Advances in Nose and Lung Organoid Models for Respiratory Viral Research. Viruses, 17.","DOI":"10.3390\/v17030349"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e00237-21","DOI":"10.1128\/mSphere.00237-21","article-title":"Human Respiratory Syncytial Virus Subgroup A and B Infections in Nasal, Bronchial, Small-Airway, and Organoid-Derived Respiratory Cultures","volume":"6","author":"Rijsbergen","year":"2021","journal-title":"mSphere"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e0351121","DOI":"10.1128\/mbio.03511-21","article-title":"The Human Nose Organoid Respiratory Virus Model: An Ex Vivo Human Challenge Model To Study Respiratory Syncytial Virus (RSV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pathogenesis and Evaluate Therapeutics","volume":"13","author":"Rajan","year":"2021","journal-title":"mBio"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00018-024-05307-y","article-title":"Virus neutralization assays for human respiratory syncytial virus using airway organoids","volume":"81","author":"Rijsbergen","year":"2024","journal-title":"Cell Mol. Life Sci."},{"key":"ref_53","unstructured":"World Health Organization (2026, May 27). Main Outcomes of the Meeting of the WHO Expert Committee on Biological Standardization Held from 13 to 16 October 2025. Available online: https:\/\/www.who.int\/publications."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/6\/550\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:31:49Z","timestamp":1782534709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/6\/550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":53,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["vaccines14060550"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14060550","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]}}}